Andrew Schwab

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Part of Acorda Therapeutics, Inc., Biotie Therapies AG is a holding Swiss company focused on developing drugs for the treatment of psychiatry and neurology diseases. The private company is based in Zurich, Switzerland.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

DVS Sciences Inc. develops analytical equipment and reagent for CyTOF instrument. The company was founded by Dmitry Bandura, Vladimir Baranov, Scott Tanner and olga Ornatsky in 2004 and is headquartered in Sunnyvale, CA.

Purigen Biosystems, Inc. engages in extracting, enriching and quantifying DNA and RNA from biological samples. The company was founded in 2012 by Amy Hiddessen, Klint Rose and Juan Santiago and is headquartered in Pleasanton, CA.

Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland.

Digital Gene Technologies, Inc. develops technology designed to enable researchers to measure gene expression levels in various disease models. The company is headquartered in La Jolla, CA.

Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

The California Academy of Sciences operates as a scientific and cultural institution. The Academy houses an aquarium, a planetarium a natural history museum and a rainforest. It was founded in 1853 and is headquartered in San Francisco, CA.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

RareCyte Inc. develops life science research and diagnostic that focuses on characterizing and isolating rare cells in the blood. It engages in bringing its technology to the life sciences research, drug development and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. It's ground-breaking sccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. The company was founded by Ronald Seubert in 2009 and is headquartered in Seattle, WA.

Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA.

Precision NanoSystems, Inc. manufactures equipment related to testing electricity and electrical Signals. It develops tools and processes for the development and manufacture of nanoparticles for use as medicines and in medical research. The company was founded by Robert James Taylor and Euan Ramsay in 2010 and is headquartered in Vancouver, Canada.

Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA.

Novome Biotechnologies, Inc. operates as a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company was founded by William DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ in 2016 and is headquartered in South San Francisco, CA.

Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom.

Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.

Nido Biosciences, Inc. focuses on developing small molecule therapeutics for the treatment of neurodegenerative diseases. The company is headquartered in Boston, MA.

TMRW Life Sciences, Inc. operates as a platform for in-clinic and remote storage. The company was founded by Joshua Abram, Alan Murray and Jeffrey Port and is headquartered in New York, NY.

5:01 Acquisition Corp. is a blank check emerging growth company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 31, 2020 and is headquartered in San Francisco, CA.

Fellow Health, Inc. is a company that offers at-home fertility testing for men. Fellow Health is based in San Leandro, CA and was founded by Graham Gilkerson and William Matthews. The company's service allows men to test their sperm privately from home and receive a doctor-reviewed male fertility report with detailed semen analysis results. In addition to their at-home testing service, the company also helps clinicians streamline their workflows and improve patient experience. William Matthews has been the CEO since incorporation.

Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024.